Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: A prospective multi-centre individual patient data analysis

PLoS ONE

Volumn 4, Issue 7, 2009, Pages

  Zwang, Julien ^a   Ashley, Elizabeth A ^a   Karema, Corine ^f,g   D'Alessandro, Umberto ^g   Smithuis, Frank ^d   Dorsey, Grant ^h   Janssens, Bart ^d   Mayxay, Mayfong ^c,e,i   Newton, Paul ^e   Singhasivanon, Pratap ^b   Stepniewska, Kasia ^b,c   White, Nicholas J ^b,c   Nosten, François ^a,b,c  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e MAHOSOT HOSPITAL   (Laos)

^f National Malaria Control Program   (Rwanda)

^g INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF HEALTH SCIENCES   (Laos)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; AMODIAQUINE PLUS FANSIDAR; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUO COTECXIN; MEFLOQUINE; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; QUINOLINE DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGITATION; ANOREXIA; ANURIA; ARTHRALGIA; ARTICLE; CAMBODIA; CHILD; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; ETHNIC DIFFERENCE; FATIGUE; FEMALE; GAMETOCYTE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEARING DISORDER; HEART PALPITATION; HEMODYNAMICS; HUMAN; INFANT; INFECTION RISK; JAUNDICE; LAOS; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTICENTER STUDY; MYALGIA; MYANMAR; NAUSEA; NIGHTMARE; PARESTHESIA; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RWANDA; SEIZURE; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; THAILAND; TINNITUS; TREATMENT RESPONSE; UGANDA; URTICARIA; VISUAL DISORDER; VOMITING; WEAKNESS; AGED; MIDDLE AGED; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ARTESUNATE;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 68149158508     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006358     Document Type: Article

References (33)

1. WHO (2006) Guidelines for the treatment of malaria (WHO/HTM/MAL/ 2006.1108), available at: http://www.who.int/malaria/docs/ TreatmentGuidelines2006.pdf (page 17) [accessed 2 August 2007].
2. http://www.who.int/malaria/treatmentpolicies.html [accessed 19 August 2008].
3. Hien TT, Mai PP, Dolecek C, Phuong P, Dung NT, Truong NT, Thanh N, Thai LH, An DTH, Quyen NTH, White NJ, Farrar JJ (2004) Dihydroartemisinin-piperaquine against multidrug resistant falciparum malaria in Viet Nam: randomized clinical trial. Lancet 363: 18-22.
4. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, et al. (2008) Population pharmacokinetics of piperaquine after two different treatment regimens of dihydroartemisinin-piperaquine in patients with acute uncomplicated Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 52: 1052-61.
5. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, et al. (2004) Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 57: 253-262.
6. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, Hutagalung R, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White NJ (2004) Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis 190: 1773-82.
7. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, et al. (2005) A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 41: 425-32.
8. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, et al. (2006) Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367: 2075-85.
9. Karema C, Fanello CI, Van Overmeir C, Van Geertruyden JP, van Doren W, et al. (2006) Safety and efficacy of dihydroartemisinin/piperaquine (Artekin®) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 100: 1105-11.
10. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G (2007) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2(5): e20.
11. Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N, Barends M, et al. (2006) An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodiumfalciparum malaria in the Lao People's Democratic Republic (Laos). Trop Med Int Health 11: 1157-65.
12. Janssens B, van Herp M, Goubert L, Chan S, Uong S, et al. (2007) A randomised open study to assess the efficacy and tolerability of Dihydroartemisinin - Piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 12: 251-9.
13. Brockman A, Paul RE, Anderson TJ, Hackford I, Phaiphun L, et al. (1999) Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg 60: 14-21.
14. Irion A, Felger I, Abdulla S, Smith T, Mull R, et al. (1998) Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in Tanzanian children. Trop Med Int Health 3: 490-7.
15. Snounou G, Singh B (2002) Nested PCR analysis of Plasmodium parasites. Methods Mol Med 72: 189-203.
16. Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, et al. (2004) Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg 75: 836-42.
17. Juni B, Altman DG, Egger M (2001) Systematic reviews of healthcare: assessing the quality of controlled clinical trials. BMJ 323: 42-46.
18. Stepniewska K, White NJ (2006) Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 22: 127.
19. Hightower AW, Orenstein WA, Martin SM (1988) Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy. Bull World Health Organ 66: 99-105.
20. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, et al. (1996) Effects of artemisinin derivatives on malaria transmissibility. Lancet 347: 1654-8.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-60.
22. Pocock SJ, Travison TG, Wruck LM (2008) How to interpret figures in reports of clinical trials. BMJ 336: 1166-9.
23. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, et al. (2008) A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 11: 2545-57.
24. Rwagacondo CE, Karema C, Mugisha V, Erhart A, Dujardin JC, et al. (2004) Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health 9: 1091-8.
25. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, et al. (2007) Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin piperaquine for drug resistant malaria. Antimicrob Agents Chemother 51: 4090-7.
26. Chinh NT, Quang NN, Thanh NX, Dai B, Travers T, et al. (2008) Pharmacokinetics of the Antimalarial Drug Piperaquine in Healthy Vietnamese Subjects. Am J Trop Med Hyg 79(4): 620-623.
27. Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, et al. (2008) A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J 7: 237.
28. Grande T, Bernasconi A, Erhart A, Gamboa D, Casapia M, et al. (2007) A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS ONE 2(10).
29. Barnes KI, Little F, Mabuza A, Mngomezulu N, Govere J, et al. (2008) Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. J Infect Dis 197: 1605-13.
30. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, et al. (2007) Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 927-33.
31. White NJ, The assessment of antimalarial drug efficacy (2002) Trends Parasitol 18: 458-64.
32. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF (2005) Piperaquine: a resurgent antimalarial drug. Drugs 65: 75-87.
33. Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, et al. (2007) World Antimalarial Resistance Network (WARN) I: Clinical efficacy of antimalarial therapy. Malar J 6: 119.